Efficacy of nylidrin hydrochloride in the treatment of cognitive impairment in the elderly.
A double-blind study was conducted on the effects of nylidrin hydrochloride versus placebo in 60 patients with mild to moderate symptoms of chronic brain syndrome. Their ages ranged from 65 to 99 years. Preliminary results indicated that nylidrin HCl (a vasodilator) is a relatively safe therapeutic agent and more effective than placebo in ameliorating the symptoms of cognitive impairment associated with aging, on both a short term (3-month) and a long-term (9-month) basis. In a dosage of 24 mg daily, it reached its peak effectiveness after 3 months of use.
D000368:Aged; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009756:Nylidrin / Q000627:therapeutic use*; D012919:Social Behavior
D009756:Nylidrin